A. Kokko

Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data

P. Hannonen, H. Kautiainen, T. Sokka, 2015, Expert Opinion on Biological Therapy.

Short interruptions of TNF-inhibitor treatment can be associated with treatment failure in patients with immune-mediated diseases

H. Mäkinen, T. Jokiranta, K. Aalto, 2022, Autoimmunity.

Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naive Rheumatoid Arthritis

P. Hannonen, T. Sokka, T. Rannio, 2016, The Journal of Rheumatology.

Similar clinical outcomes in rheumatoid arthritis with more versus less expensive treatment strategies. Observational data from two rheumatology clinics.

P. Hannonen, G. Haugeberg, T. Sokka, 2013, Clinical and experimental rheumatology.

Immunogenicity of subcutaneous TNF inhibitors and its clinical significance in real-life setting in patients with spondyloarthritis

T. Jokiranta, J. Rutanen, M. Leirisalo-Repo, 2021, Rheumatology International.